Antitumor effects of (S)-HDAC42, a phenylbutyrate-derived histone deacetylase inhibitor, in multiple myeloma cells.

There is no author summary for this article yet. Authors can add summaries to their articles on ScienceOpen to make them more accessible to a non-specialist audience.

Abstract

Epigenetic agents are among the newly targeted therapeutic strategies being studied with intense interest for patients with multiple myeloma. Here, we demonstrate the antitumor activity of a phenylbutyrate-based histone deacetylase (HDAC) inhibitor, (S)-HDAC42, and identify its possible targets in myeloma cells.

Related collections

Author and article information

Journal

Journal ID (iso-abbrev): Cancer Chemother. Pharmacol.

Title: Cancer chemotherapy and pharmacology

Publisher: Springer Nature America, Inc

ISSN (Electronic): 1432-0843

ISSN (Print): 0344-5704

Publication date (Electronic): Aug 2011

Volume: 68

Issue: 2

Affiliations

[1 ] Graduate Institute of Clinical Medical Science, China Medical University, Taichung, Taiwan.

Article

DOI: 10.1007/s00280-010-1501-z

PubMed ID: 21072520

SO-VID: 332a7737-d628-44d7-9322-f476a91f5f79

History

Data availability:

Comments

Comment on this article

scite_

Cited by 5

See all cited by